PMID- 28650560
OWN - NLM
STAT- MEDLINE
DCOM- 20181010
LR  - 20181010
IS  - 1600-0714 (Electronic)
IS  - 0904-2512 (Linking)
VI  - 47
IP  - 3
DP  - 2018 Mar
TI  - Uncovering the role of brain-derived neurotrophic factor/tyrosine kinase receptor 
      B signaling in head and neck malignancies.
PG  - 221-227
LID - 10.1111/jop.12611 [doi]
AB  - Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family 
      of growth factors that was first known as responsible for sustain the growth, 
      function, and plasticity of neural cells. BDNF exerts its effects by binding to 
      the tyrosine kinase receptor B (TrkB). The BDNF/TrkB axis has been reported to be 
      overexpressed in several neurogenic and non-neurogenic tumors. Its higher 
      expression was associated with a poor prognosis to patients affected by different 
      human malignancies, tumor growth, invasion, and metastasis; 
      epithelial-mesenchymal transition and resistance to chemotherapy. BDNF/TrkB 
      represent promising targets to the development of novel anticancer therapies. 
      Some clinical trials are currently evaluating the efficacy of Trk protein-target 
      drugs in different types of solid tumors. To date, few groups have evaluated the 
      DNF/TrkB pathway in head and neck malignancies. The aims of this study were to 
      review the literature concerning the role of BDNF/TrkB activation in head and 
      neck squamous cell carcinoma and malignant salivary gland tumors and to discuss 
      future perspectives of BDNF/TrkB-target therapy.
CI  - (c) 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - de Moraes, Juliana Kern
AU  - de Moraes JK
AD  - Department of Oral Diagnosis, Piracicaba Dental School, University of Campinas, 
      Piracicaba, Brazil.
FAU - Wagner, Vivian Petersen
AU  - Wagner VP
AD  - Department of Pathology, School of Dentistry, Federal University of Rio Grande do 
      Sul, Porto Alegre, Brazil.
FAU - Fonseca, Felipe Paiva
AU  - Fonseca FP
AUID- ORCID: 0000-0002-6657-4547
AD  - Department of Oral Surgery and Pathology, School of Dentistry, Universidade 
      Federal de Minas Gerais, Belo Horizonte, Brazil.
FAU - Vargas, Pablo Agustin
AU  - Vargas PA
AD  - Department of Oral Diagnosis, Piracicaba Dental School, University of Campinas, 
      Piracicaba, Brazil.
FAU - de Farias, Caroline Brunetto
AU  - de Farias CB
AD  - Cancer and Neurobiology Laboratory, Experimental Research Center, Porto Alegre 
      Clinical Hospital, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
AD  - Children's Cancer Institute, Porto Alegre, Brazil.
FAU - Roesler, Rafael
AU  - Roesler R
AD  - Cancer and Neurobiology Laboratory, Experimental Research Center, Porto Alegre 
      Clinical Hospital, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
AD  - Department of Pharmacology, Institute for Basic Health Sciences, Federal 
      University of Rio Grande do Sul, Porto Alegre, Brazil.
FAU - Martins, Manoela Domingues
AU  - Martins MD
AUID- ORCID: 0000-0001-8662-5965
AD  - Department of Oral Diagnosis, Piracicaba Dental School, University of Campinas, 
      Piracicaba, Brazil.
AD  - Department of Pathology, School of Dentistry, Federal University of Rio Grande do 
      Sul, Porto Alegre, Brazil.
AD  - Experimental Pathology Unit, Hospital de Clinicas de Porto Alegre, Porto Alegre, 
      Brazil.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170722
PL  - Denmark
TA  - J Oral Pathol Med
JT  - Journal of oral pathology & medicine : official publication of the International 
      Association of Oral Pathologists and the American Academy of Oral Pathology
JID - 8911934
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - EC 2.7.10.1 (Receptor, trkB)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Antineoplastic Agents/pharmacology
MH  - Brain-Derived Neurotrophic Factor/*metabolism
MH  - Carcinoma, Adenoid Cystic/drug therapy/metabolism/pathology
MH  - Carcinoma, Mucoepidermoid/drug therapy/metabolism/pathology
MH  - Carcinoma, Squamous Cell/drug therapy/metabolism
MH  - Cisplatin/pharmacology
MH  - Drug Resistance, Neoplasm
MH  - Head and Neck Neoplasms/drug therapy/*metabolism/pathology
MH  - Humans
MH  - Neoplasm Invasiveness
MH  - Prognosis
MH  - Receptor, trkB/*metabolism
OTO - NOTNLM
OT  - adenoid cystic carcinoma
OT  - head and neck cancer
OT  - oral squamous cell carcinoma
OT  - salivary gland cancer
OT  - signaling pathway
EDAT- 2017/06/27 06:00
MHDA- 2018/10/12 06:00
CRDT- 2017/06/27 06:00
PHST- 2017/06/22 00:00 [accepted]
PHST- 2017/06/27 06:00 [pubmed]
PHST- 2018/10/12 06:00 [medline]
PHST- 2017/06/27 06:00 [entrez]
AID - 10.1111/jop.12611 [doi]
PST - ppublish
SO  - J Oral Pathol Med. 2018 Mar;47(3):221-227. doi: 10.1111/jop.12611. Epub 2017 Jul 
      22.